Long classified as a Schedule 1 drug, one which has “no medical use and a high potential abuse,” marijuana shares its status with drugs like heroin and is more strictly regulated than opioids prescribed legally to medically relieve pain by producing morphine-like effects.
But, while the drug remains illegal on a federal level, the tide of public opinion has been shifting and medical scientists are claiming a government-sanctioned mono-poly on the supply of cannabis for studies is stifling advancement of research.
The Drug Enforcement Administration now plans to take a second look at that classification and determine whether the drug’s threat should be downgraded. But, researchers shouldn’t hold their breath. The agency promised that before in 2001 and 2006 without making a change.
In a memo issued to lawmakers in April, the DEA said that it hopes to issue a decision in “the first half of 2016” whether to remove the Schedule 1 drug classification under the Controlled Substances Act. The memo was issued jointly by the DEA, U.S. Department of Health and the Office of National Drug Control Policy.
Under fire by researchers, those studying the drug for possible medicinal treatments say that under the harsh classification, they lack access to adequate supplies and varying strains of cannabis because the DEA only sanctions a marijuana garden at the University of Mississippi. The DEA has said it may consider registering additional growers.
“These knowledge limitations exist because the U.S. government has made cannabis illegal on the basis of its having no medical value,” wrote Brookings Institution John Hudak in a piece titled “Fixing the Medical Marijuana Mess - A prescription for fixing a broken policy.”
“By prohibiting it, the government has made it harder for researchers to investigate what its medical value might actually be. This is the vicious cycle of marijuana prohibition,” Hudak wrote.
